GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer (ES‑SCLC). Results from the Phase Ib dose‑optimization portion of the EMBOLD PanTumour‑101 trial showed positive anti‑tumor activity and a manageable safety profile, adding to recently reported positive Phase III data in patients with SCLC in China. At the selected 8 mg/kg dose, Ris‑Rez achieved a confirmed objective response rate (ORR) of 61% among evaluable patients.
Clinical Milestone
| Item | Detail |
|---|---|
| Company | GlaxoSmithKline Plc (GSK; NYSE: GSK) |
| Asset | Risvutatug rezetecan (Ris‑Rez, HS‑20093) – investigational B7‑H3‑targeted ADC |
| Trial | EMBOLD PanTumour‑101 – Phase Ib, dose‑optimization portion |
| Population | Relapsed extensive‑stage small cell lung cancer (ES‑SCLC) |
| Key Result | Confirmed ORR 61% at 8 mg/kg (n=11/18) vs. 32% at 6 mg/kg (n=7/22) |
| Safety | Manageable safety profile |
| Data Date | 18 Oct 2026 (first global data) |
| Corroborating Evidence | Recently reported positive Phase III SCLC data in China |
Clinical Evidence – Phase Ib Dose Optimization
| Dose | Confirmed ORR | n/N (Evaluable) | 95% CI |
|---|---|---|---|
| 8 mg/kg | 61 % | 11/18 | 35.7–82.7 |
| 6 mg/kg | 32 % | 7/22 | 13.9–54.9 |
The EMBOLD PanTumour‑101 Phase Ib dose‑optimization data demonstrate a clear dose‑response signal, with the 8 mg/kg cohort nearly doubling the confirmed ORR of the 6 mg/kg cohort, alongside what GSK described as a manageable safety profile. The readout reinforces recently reported positive Phase III results in SCLC patients in China, building a coherent global evidence package for the B7‑H3 ADC in small cell lung cancer.
Drug Profile & Mechanism of Action
- Molecule: Risvutatug rezetecan (Ris‑Rez, HS‑20093) – a novel investigational antibody‑drug conjugate.
- Target: B7‑H3, an immunomodulatory protein highly expressed in more than 10 solid tumor types, providing a broad tumor‑selective delivery route for the cytotoxic payload.
- Origin: Originally developed by Hansoh Pharma.
- Acquisition: In December 2023, GSK acquired the ex‑China rights to the drug in a deal valued at over USD 1.7 billion.
- Development Ambition: GSK plans to explore up to 40 potential indications for Ris‑Rez by 2040, positioning the asset as a platform‑scale franchise rather than a single‑indication product.
Market Impact & Outlook
- ES‑SCLC Unmet Need: Relapsed extensive‑stage SCLC remains one of the most treatment‑refractory solid tumors; a 61% confirmed ORR in the Phase Ib setting would be a notable efficacy signal for this population.
- Global‑China Evidence Convergence: The combination of EMBOLD PanTumour‑101 global data and positive Phase III SCLC data in China strengthens the registrational narrative across both Hansoh’s home market and GSK’s ex‑China territory.
- B7‑H3 Class Momentum: With B7‑H3 expressed across more than 10 solid tumor types, GSK’s plan for up to 40 indications by 2040 reflects the company’s ambition to establish Ris‑Rez as a multi‑tumor ADC franchise.
- Deal Validation: The readout marks an early clinical validation of GSK’s USD 1.7 billion+ ex‑China licensing investment in Hansoh’s ADC pipeline.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the development of risvutatug rezetecan, including trial progression, potential indications and regulatory pathways. Actual results may differ materially due to risks including subsequent trial outcomes, safety findings in larger populations, regulatory review requirements, and competitive dynamics. Early‑phase clinical data do not guarantee eventual marketing approval of the investigational product.-Fineline Info & Tech
